Increasing the efficacy of oncolytic adenovirus vectors

Viruses

Volumn 2, Issue 9, 2010, Pages 1844-1866

  Toth, Karoly ^a   Wold, William S M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus; Replication competent; Tumor; Virotherapy

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CYTOSINE DEAMINASE; ENDOSTATIN; FLUOROURACIL; FOLINIC ACID; HYPERIMMUNE GLOBULIN; ICOVIR 7; KD 3; LIPOSOME; MACROGOL; NEUTRALIZING ANTIBODY; NITROREDUCTASE; ONCOLYTIC ADENOVIRUS; ONCOLYTIC VIRUS; ONCORINE; ONYX 015; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE]; PRODRUG; PROSTATE SPECIFIC ANTIGEN; THYMIDINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VIROTHERAPY AGENT; VRX 007;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CYTOLYSIS; DNA MODIFICATION; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TRANSFORMATION; GENE EXPRESSION REGULATION; GENETIC GAIN; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOCOMPETENCE; IMMUNOMODULATION; IN VIVO STUDY; LIPOSOMAL DELIVERY; LIVER TOXICITY; LUNG CANCER; NEOPLASM; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY TUMOR; PASSIVE IMMUNIZATION; PROSTATE CANCER; PROSTATE TUMOR; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TOXICITY TESTING; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; VIRAL CLEARANCE; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 79952151242     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2091844     Document Type: Review

References (141)

1. Toth, K.; Dhar, D.; Wold, W.S. Oncolytic (replication-competent) adenoviruses as anticancer agents. Exp. Opin. Biol. Ther. 2010, 10, 353-368.
2. Wold, W.S.M.; Horwitz, M.S. Adenoviruses. In Field's Virology, 5th Edition; Knipe D.M., Howley P.M., Eds.; Lippincott, Williams, & Wilkins, Philadelphia, PA, USA. 2007; pp. 2395-2436.
3. Lichtenstein, D.L.; Wold, W.S.M. Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther. 2004, 11, 819-829.
4. Berk, A.J. Adenoviridae: The Viruses and Their Replication. In Field's Virology, 5th Edition; Knipe D.M., Howley P.M., Eds.; Lippincott, Williams, & Wilkins, Philadelphia, PA, USA. 2007; pp. 2355-2394.
5. Russell, W.C. Adenoviruses: update on structure and function. J. Gen. Virol 2009, 90, 1-20.
6. Bett, A.J.; Haddara, W.; Prevec, L.; Graham, F.L. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 8802-8806.
7. He, T.C.; Zhou, S.; da Costa, L.T.; Yu, J.; Kinzler, K.W.; Vogelstein, B. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 2509-2514.
8. O'Shea, C.C. Viruses - seeking and destroying the tumor program. Oncogene 2005, 24, 7640-7655
9. Bischoff, J.R.; Kirn, D.H.; Williams, A.; Heise, C.; Horn, S.; Muna, M.; Ng, L.; Nye, J.A.; Sampson-Johannes, A.; Fattaey, A.; McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274, 373-376.
10. Heise, C.; Ganly, I.; Kim, Y.T.; Sampson-Johannes, A.; Brown, R.; Kirn, D. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther. 2000, 7, 1925-1929.
11. Heise, C.C.; Williams, A.M.; Xue, S.; Propst, M.; Kirn, D.H. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 1999, 59, 2623-2628.
12. Spencer, J.F.; Sagartz, J.E.; Wold, W.S.M.; Toth, K. New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster. Cancer Gene Ther. 2009, 16, 912-922.
13. Toth, K.; Kuppuswamy, M.; Shashkova, E.V.; Spencer, J.F.; Wold, W.S.M. A fully replication-competent vector with enhanced oncolytic properties. Cancer Gene Ther. 2010, doi: 10.1038/cgt.2010.33.
14. Lichtenstein, D.L.; Spencer, J.F.; Doronin, K.; Patra, D.; Meyer, J.; Shashkova, E.V.; Kuppuswamy, M.; Dhar, D.; Thomas, M.A.; Tollefson, A.E.; Zumstein, L.A.; Wold, W.S.M.; Toth, K. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Ther. 2009, 16, 644-654.
15. Ribacka, C.; Hemminki, A. Virotherapy as an approach against cancer stem cells. Current Gene Ther. 2008, 8, 88-96.
16. Fukazawa, T.; Matsuoka, J.; Yamatsuji, T.; Maeda, Y.; Durbin, M.L.; Naomoto, Y. Adenovirus-mediated cancer gene therapy and virotherapy. International Journal of Molecular Medicine. 2010, 25, 3-10.
17. Jiang, H.; Gomez-Manzano, C.; Lang, F.F.; Alemany, R.; Fueyo, J. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Current Gene Ther. 2009, 9, 422-427.
18. Alemany, R. Designing adenoviral vectors for tumor-specific targeting. Methods Mol. Biol. 2009, 542, 57-74.
19. Harada, J.N.; Berk, A.J. p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol. 1999, 73, 5333-5344.
20. O'Shea, C.C.; Johnson, L.; Bagus, B.; Choi, S.; Nicholas, C.; Shen, A.; Boyle, L.; Pandey, K.; Soria, C.; Kunich, J.; Shen, Y.; Habets, G.; Ginzinger, D.; McCormick, F. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004, 6, 611-623.
21. O'Shea, C.C.; Soria, C.; Bagus, B.; McCormick, F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 2005, 8, 61-74.
22. Heise, C.; Sampson-Johannes, A.; Williams, A.; McCormick, F.; Von Hoff, D.D.; Kirn, D.H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med. 1997, 3, 639-645.
23. Heise, C.C.; Williams, A.; Olesch, J.; Kirn, D.H. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther. 1999, 6, 499-504.
24. Hartman, Z.C.; Appledorn, D.M.; Amalfitano, A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res. 2008, 132, 1-14.
25. Thomas, M.A.; Spencer, J.F.; La Regina, M.C.; Dhar, D.; Tollefson, A.E.; Toth, K.; Wold, W.S. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res. 2006, 66, 1270-1276.
26. Bortolanza, S.; Alzuguren, P.; Bunuales, M.; Qian, C.; Prieto, J.; Hernandez-Alcoceba, R. Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters. Human Gene Ther. 2007, 18, 681-690.
27. Sonabend, A.M.; Ulasov, I.V.; Han, Y.; Rolle, C.E.; Nandi, S.; Cao, D.; Tyler, M.A.; Lesniak, M.S. Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats. Cancer Gene Ther. 2008, 16, 362-372.
28. Thomas, M.A.; Spencer, J.F.; Toth, K.; Sagartz, J.E.; Phillips, N.; Wold, W.S.M. Immunosuppression enhances oncolytic adenovirus replication and anti tumor efficacy in the Syrian hamster model. Mol. Ther. 2008, 16, 1665-1673.
29. Ying, B.; Toth, K.; Spencer, J.F.; Meyer, J.; Tollefson, A.E.; Patra, D.; Dhar, D.; Shashkova, E.V.; Kuppuswamy, M.; Doronin, K.; Thomas, M.A.; Zumstein, L.A.; Wold, W.S.M.; Lichtenstein, D.L. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. Cancer Gene Ther. 2009, 16, 625-637.
30. Toth, K.; Spencer, J.F.; Dhar, D.; Sagartz, J.E.; Buller, R.M.; Painter, G.R.; Wold, W.S.M. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 7293-7297.
31. Kumar, S.; Gao, L.; Yeagy, B.; Reid, T. Virus combinations and chemotherapy for the treatment of human cancers. Curr. Opin. Mol. Ther. 2008, 10, 371-379.
32. Alemany, R. Cancer selective adenoviruses. Mol. Aspects Med. 2007, 28, 42-58.
33. Crompton, A.M.; Kirn, D.H. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr. Cancer Drug Targets 2007, 7, 133-139.
34. Lu, W.; Zheng, S.; Li, X.F.; Huang, J.J.; Zheng, X.; Li, Z. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J. Gastroenterol. 2004, 10, 3634-3638.
35. Yu, W.; Fang, H. Clinical trials with oncolytic adenovirus in China. Current Cancer Drug Targets 2007, 7, 141-148.
36. Jia, H.; Kling, J. China offers alternative gateway for experimental drugs. Nat. Biotechnol. 2006, 24, 117-118.
37. Garber, K. China approves world's first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst. 2006, 98, 298-300.
38. Habib, N.; Salama, H.; Abd El Latif Abu Median; Isac, A., I; Abd Al Aziz, R.A.; Sarraf, C.; Mitry, R.; Havlik, R.; Seth, P.; Hartwigsen, J.; Bhushan, R.; Nicholls, J.; Jensen, S. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther. 2002, 9, 254-259.
39. Reid, T.; Galanis, E.; Abbruzzese, J.; Sze, D.; Andrews, J.; Romel, L.; Hatfield, M.; Rubin, J.; Kirn, D. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther. 2001, 8, 1618-1626.
40. Reid, T.R.; Freeman, S.; Post, L.; McCormick, F.; Sze, D.Y. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther. 2005, 12, 673-681.
41. Sze, D.Y.; Freeman, S.M.; Slonim, S.M.; Samuels, S.L.; Andrews, J.C.; Hicks, M.; Ahrar, K.; Gupta, S.; Reid, T.R.; Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival. J. Vasc. Interv. Radiol. 2003, 14, 279-290.
42. Au, T.; Thorne, S.; Korn, W.M.; Sze, D.; Kirn, D.; Reid, T.R. Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver. Cancer Gene Ther. 2007, 14, 139-150.
43. Reid, T.; Galanis, E.; Abbruzzese, J.; Sze, D.; Wein, L.M.; Andrews, J.; Randlev, B.; Heise, C.; Uprichard, M.; Hatfield, M.; Rome, L.; Rubin, J.; Kirn, D. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002, 62, 6070-6079.
44. Freytag, S.O.; Stricker, H.; Movsas, B.; Kim, J.H. Prostate cancer gene therapy clinical trials. Mol. Ther. 2007, 15, 1042-1052.
45. Freytag, S.O.; Khil, M.; Stricker, H.; Peabody, J.; Menon, M.; DePeralta-Venturina, M.; Nafziger, D.; Pegg, J.; Paielli, D.; Brown, S.; Barton, K.; Lu, M.; Aguilar-Cordova, E.; Kim, J.H. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002, 62, 4968-4976.
46. Freytag, S.O.; Stricker, H.; Pegg, J.; Paielli, D.; Pradhan, D.G.; Peabody, J.; DePeralta-Venturina, M.; Xia, X.; Brown, S.; Lu, M.; Kim, J.H. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 2003, 63, 7497-7506.
47. Freytag, S.O.; Stricker, H.; Peabody, J.; Pegg, J.; Paielli, D.; Movsas, B.; Barton, K.N.; Brown, S.L.; Lu, M.; Kim, J.H. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol. Ther. 2007, 15, 636-642.
48. DeWeese, T.; Arterbery, E.; Michalski, J.; Sylvester, J.E.; Terris, M.K.; Wilding, G.; Yu, D.C.; Moore, L.; Kimball, L.; Ando, D.; Kirn, D. A Phase I/II dose escalation trial of the intra prostatic injection of CG7870, a prostate specific antigen-dependent oncolytic adenovirus in patients with locally recurrent prostate cancer following definitive radiotherapy. Cancer Gene Ther. 2003, 10, S13-S14.
49. DeWeese, T.L.; van der Poel, H.; Li, S.; Mikhak, B.; Drew, R.; Goemann, M.; Hamper, U.; DeJong, R.; Detorie, N.; Rodriguez, R.; Haulk, T.; Demarzo, A.M.; Piantadosi, S.; Yu, D.C.; Chen, Y.; Henderson, D.R.; Carducci, M.A.; Nelson, W.G.; Simons, J.W. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001, 61, 7464-7472.
50. Small, E.J.; Carducci, M.A.; Burke, J.M.; Rodriguez, R.; Fong, L.; van Ummersen, L.; Yu, D.C.; Aimi, J.; Ando, D.; Working, P.; Kirn, D.; Wilding, G. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol. Ther. 2006, 14, 107-117.
51. Pesonen, S.; Helin, H.; Nokisalmi, P.; Escutenaire, S.; Ribacka, C.; Sarkioja, M.; Cerullo, V.; Guse, K.; Bauerschmitz, G.; Laasonen, L.; Kantola, T.; Ristimaki, A.; Rajecki, M.; Oksanen, M.; Haavisto, E.; Kanerva, A.; Joensuu, T.; Hemminki, A. Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. Acta Oncol. 2010, 49, 120-122.
52. Pesonen, S.; Nokisalmi, P.; Escutenaire, S.; Sarkioja, M.; Raki, M.; Cerullo, V.; Kangasniemi, L.; Laasonen, L.; Ribacka, C.; Guse, K.; Haavisto, E.; Oksanen, M.; Rajecki, M.; Helminen, A.; Ristimaki, A.; Karioja-Kallio, A.; Karli, E.; Kantola, T.; Bauerschmitz, G.; Kanerva, A.; Joensuu, T.; Hemminki, A. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther 2010, 17, 892-904.
53. Nokisalmi, P.; Pesonen, S.; Escutenaire, S.; Ristimki, A.; Joensuu, T.; Guse, K.; Srkioja, M.; Hemminki, A. Clinical data from cancer patients treated with triple modified oncolytic adenovirus Ad5/3-Cox2L-D24. Human Gene Ther. 2008, 19, 1076.
54. Nokisalmi, P.; Pesonen, S.; Escutenaire, S.; Sarkioja, M.; Raki, M.; Cerullo, V.; Laasonen, L.; Alemany, R.; Rojas, J.; Cascallo, M.; Guse, K.; Rajecki, M.; Kangasniemi, L.; Haavisto, E.; Karioja-Kallio, A.; Hannuksela, P.; Oksanen, M.; Kanerva, A.; Joensuu, T.; Ahtiainen, L.; Hemminki, A. Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors. Clin. Cancer. Res. 2010, 16, 3035-3043.
55. Cerullo, V.; Pesonen, S.; Diaconu, I.; Escutenaire, S.; Arstila, P.T.; Ugolini, M.; Nokisalmi, P.; Raki, M.; Laasonen, L.; Sarkioja, M.; Rajecki, M.; Kangasniemi, L.; Guse, K.; Helminen, A.; Ahtiainen, L.; Ristimaki, A.; Raisanen-Sokolowski, A.; Haavisto, E.; Oksanen, M.; Karli, E.; Karioja-Kallio, A.; Holm, S.L.; Kouri, M.; Joensuu, T.; Kanerva, A.; Hemminki, A. Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients. Cancer Res. 2010, 70, 4297-4309.
56. Sauthoff, H.; Hu, J.; Maca, C.; Goldman, M.; Heitner, S.; Yee, H.; Pipiya, T.; Rom, W.N.; Hay, J.G. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum. Gene Ther. 2003, 14, 425-433.
57. Kuhn, I.; Harden, P.; Bauzon, M.; Chartier, C.; Nye, J.; Thorne, S.; Reid, T.; Ni, S.; Lieber, A.; Fisher, K.; Seymour, L.; Rubanyi, G.M.; Harkins, R.N.; Hermiston, T.W. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One. 2008, 3, e2409.
58. Gros, A.; Martinez-Quintanilla, J.; Puig, C.; Guedan, S.; Mollevi, D.G.; Alemany, R.; Cascallo, M. Bioselection of a Gain of Function Mutation that Enhances Adenovirus 5 Release and Improves Its Antitumoral Potency. Cancer Res. 2008, 68, 8928-8937.
59. Subramanian, T.; Vijayalingam, S.; Chinnadurai, G. Genetic identification of adenovirus type 5 genes that influence viral spread. J. Virol. 2006, 80, 2000-2012.
60. Yan, W.; Kitzes, G.; Dormishian, F.; Hawkins, L.; Sampson-Johannes, A.; Watanabe, J.; Holt, J.; Lee, V.; Dubensky, T.; Fattaey, A.; Hermiston, T.; Balmain, A.; Shen, Y.Q. Developing novel oncolytic adenoviruses through bioselection. J. Virol. 2003, 77, 2640-2650.
61. Vaillancourt, M.; Atencio, I.; Quijano, E.; Howe, J.A.; Ramachandra, M. Inefficient killing of quiescent human epithelial cells by replicating adenoviruses: potential implications for their use as oncolytic agents. Cancer Gene Ther. 2005, 12, 691-698.
62. Dhar, D.; Spencer, J.F.; Toth, K.; Wold, W.S. Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model. Mol. Ther 2009, 17, 1724-1732.
63. Doronin, K.; Toth, K.; Kuppuswamy, M.; Krajcsi, P.; Tollefson, A.E.; Wold, W.S.M. Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 2003, 305, 378-387.
64. Lichtenstein, D.L.; Toth, K.; Doronin, K.; Tollefson, A.E.; Wold, W.S.M. Functions and mechanisms of action of the adenovirus E3 proteins. Int. Rev. Immunol. 2004, 23, 75-111.
65. Doronin, K.; Toth, K.; Kuppuswamy, M.; Ward, P.; Tollefson, A.E.; Wold, W.S.M. Tumor-specific, replication-competent adenovirus vectors overexpressing the Adenovirus Death Protein. J. Virol. 2000, 74, 6147-6155.
66. Toth, K.; Tarakanova, V.; Doronin, K.; Ward, P.; Kuppuswamy, M.; Locke, J.L.; Dawson, J.E.; Kim, H.J.; Wold, W.S.M. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Ther. 2003, 10, 193-200.
67. Barton, K.N.; Xia, X.; Yan, H.; Stricker, H.; Heisey, G.; Yin, F.F.; Nagaraja, T.N.; Zhu, G.; Kolozsvary, A.; Fenstermacher, J.D.; Lu, M.; Kim, J.H.; Freytag, S.O.; Brown, S.L. A quantitative method for measuring gene expression magnitude and volume delivered by gene therapy vectors. Mol. Ther. 2004, 9, 625-631.
68. Reid, T.; Warren, R.; Kirn, D. Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther. 2002, 9, 979-986.
69. Ramesh, N.; Ge, Y.; Ennist, D.L.; Zhu, M.; Mina, M.; Ganesh, S.; Reddy, P.S.; Yu, D.C. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer. Clin. Cancer Res. 2006, 12, 305-313.
70. Tao, Z.; Connor, R.J.; Dinney, C.P.; Munsell, M.; Philopena, J.A.; Benedict, W.F. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Cancer Gene Ther. 2006, 13, 125-130.
71. Ramesh, N.; Memarzadeh, B.; Ge, Y.; Frey, D.; Vanroey, M.; Rojas, V.; Yu, D.C. Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium. Mol. Ther. 2004, 10, 697-705.
72. Komarova, S.; Kawakami, Y.; Stoff-Khalili, M.A.; Curiel, D.T.; Pereboeva, L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther. 2006, 5, 755-766.
73. Hall, B.; Dembinski, J.; Sasser, A.K.; Studeny, M.; Andreeff, M.; Marini, F. Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles. Int. J. Hematol. 2007, 86, 8-16.
74. Hakkarainen, T.; Sarkioja, M.; Lehenkari, P.; Miettinen, S.; Ylikomi, T.; Suuronen, R.; Desmond, R.A.; Kanerva, A.; Hemminki, A. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Human Gene Ther. 2007, 18, 627-641.
75. Li, Y.; Pong, R.C.; Bergelson, J.M.; Hall, M.C.; Sagalowsky, A.I.; Tseng, C.P.; Wang, Z.; Hsieh, J.T. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res. 1999, 59, 325-330.
76. Dmitriev, I.; Krasnykh, V.; Miller, C.R.; Wang, M.; Kashentseva, E.; Mikheeva, G.; Belousova, N.; Curiel, D.T. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 1998, 72, 9706-9713.
77. Gimenez-Alejandre, M.; Cascallo, M.; Bayo-Puxan, N.; Alemany, R. Coagulation Factors Determine Tumor Transduction In Vivo. Human Gene Ther. 2008, 19, 1415-1419.
78. Lyle, C.; McCormick, F. Integrin alpha v beta 5 is a primary receptor for adenovirus in CAR-negative cells. Virol. J. 2010, 7, 148.
79. Shayakhmetov, D.M.; Li, Z.Y.; Ni, S.; Lieber, A. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J. Virol. 2004, 78, 5368-5381.
80. Fukazawa, T.; Matsuoka, J.; Yamatsuji, T.; Maeda, Y.; Durbin, M.L.; Naomoto, Y. Adenovirus-mediated cancer gene therapy and virotherapy. Int. J. Mol. Med. 2010, 25, 3-10.
81. Ribacka, C.; Hemminki, A. Virotherapy as an approach against cancer stem cells. Current Gene Ther. 2008, 8, 88-96.
82. Arnberg, N. Adenovirus receptors: implications for tropism, treatment and targeting. Rev. Med. Virol. 2009, 19, 165-178.
83. Nettelbeck, D.M. Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer. J. Mol. Med. 2008, 86, 363-377.
84. Shayakhmetov, D.M.; Papayannopoulou, T.; Stamatoyannopoulos, G.; Lieber, A. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J. Virol. 2000, 74, 2567-2583.
85. Gaggar, A.; Shayakhmetov, D.M.; Lieber, A. CD46 is a cellular receptor for group B adenoviruses. Nature Med. 2003, 9, 1408-1412.
86. Short, J.J.; Pereboev, A.V.; Kawakami, Y.; Vasu, C.; Holterman, M.J.; Curiel, D.T. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology 2004, 322, 349-359.
87. Krasnykh, V.; Dmitriev, I.; Mikheeva, G.; Miller, C.R.; Belousova, N.; Curiel, D.T. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J. Virol. 1998, 72, 1844-1852.
88. Wickham, T.J.; Roelvink, P.W.; Brough, D.E.; Kovesdi, I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat. Biotechnol. 1996, 14, 1570-1573.
89. Zeng, Y.; Pinard, M.; Jaime, J.; Bourget, L.; Uyen, L.P.; O'Connor-McCourt, M.D.; Gilbert, R.; Massie, B. A ligand-pseudoreceptor system based on de novo designed peptides for the generation of adenoviral vectors with altered tropism. J. Gene Med. 2008, 10, 355-367.
90. Belousova, N.; Mikheeva, G.; Gelovani, J.; Krasnykh, V. Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer. J. Virol. 2008, 82, 630-637.
91. Rittner, K.; Schreiber, V.; Erbs, P.; Lusky, M. Targeting of adenovirus vectors carrying a tumor cell-specific peptide: in vitro and in vivo studies. Cancer Gene Ther. 2007, 14, 509-518.
92. van Geer, M.A.; Bakker, C.T.; Koizumi, N.; Mizuguchi, H.; Wesseling, J.G.; Oude Elferink, R.P.; Bosma, P.J. Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivo. World J. Gastroenterol. 2009, 15, 2754-2762.
93. Krasnykh, V.; Belousova, N.; Korokhov, N.; Mikheeva, G.; Curiel, D.T. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J. Virol. 2001, 75, 4176-4183.
94. Mercier, G.T.; Campbell, J.A.; Chappell, J.D.; Stehle, T.; Dermody, T.S.; Barry, M.A. A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 6188-6193.
95. Einfeld, D.A.; Brough, D.E.; Roelvink, P.W.; Kovesdi, I.; Wickham, T.J. Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J. Virol. 1999, 73, 9130-9136.
96. Belousova, N.; Korokhov, N.; Krendelshchikova, V.; Simonenko, V.; Mikheeva, G.; Triozzi, P.L.; Aldrich, W.A.; Banerjee, P.T.; Gillies, S.D.; Curiel, D.T.; Krasnykh, V. Genetically targeted adenovirus vector directed to CD40-expressing cells. J. Virol. 2003, 77, 11367-11377.
97. Kalyuzhniy, O.; Di Paolo, N.C.; Silvestry, M.; Hofherr, S.E.; Barry, M.A.; Stewart, P.L.; Shayakhmetov, D.M. Adenovirus serotype 5 hexon is critical for virus infection of heptocytes in vivo. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 5483-5488.
98. Waddington, S.N.; Mcvey, J.H.; Bhella, D.; Parker, A.L.; Barker, K.; Atoda, H.; Pink, R.; Buckley, S.M.K.; Greig, J.A.; Denby, L.; Custers, J.; Morita, T.; Francischetti, I.M.B.; Monteiro, R.Q.; Barouch, D.H.; van Rooijen, N.; Napoli, C.; Hlavenga, M.J.E.; Nicklin, S.A.; Baker, A.H. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008, 132, 397-409.
99. Alba, R.; Bradshaw, A.C.; Parker, A.L.; Bhella, D.; Waddington, S.N.; Nicklin, S.A.; van Rooijen, N.; Custers, J.; Goudsmit, J.; Barouch, D.H.; Mcvey, J.H.; Baker, A.H. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 2009, 114, 965-971.
100. Steel, J.C.; Cavanagh, H.M.; Burton, M.A.; Abu-Asab, M.S.; Tsokos, M.; Morris, J.C.; Kalle, W.H. Increased tumor localization and reduced immune response to adenoviral vector formulated with the liposome DDAB/DOPE. Eur. J. Pharm. Sci. 2007, 30, 398-405.
101. Lee, E.M.; Hong, S.H.; Lee, Y.J.; Kang, Y.H.; Choi, K.C.; Choi, S.H.; Kim, I.H.; Lim, S.J. Liposome-complexed adenoviral gene transfer in cancer cells expressing various levels of coxsackievirus and adenovirus receptor. J. Cancer Res. Clin. Oncol. 2004, 130, 169-177.
102. Kashentseva, E.A.; Douglas, J.T.; Zinn, K.R.; Curiel, D.T.; Dmitriev, I.P. Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody. J. Mol. Biol. 2009, 388, 443-461.
103. van der Poel, H.G.; Molenaar, B.; Van Beusechem, V.W.; Haisma, H.J.; Rodriguez, R.; Curiel, D.T.; Gerritsen, W.R. Epidermal growth factor receptor targeting of replication competent adenovirus enhances cytotoxicity in bladder cancer. J. Urol. 2002, 168, 266-272.
104. Kreppel, F.; Kochanek, S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol. Ther. 2008, 16, 16-29.
105. Fisher, K.D.; Stallwood, Y.; Green, N.K.; Ulbrich, K.; Mautner, V.; Seymour, L.W. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 2001, 8, 341-348.
106. Hofherr, S.E.; Shashkova, E.V.; Weaver, E.A.; Khare, R.; Barry, M.A. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol. Ther. 2008, 16, 1276-1282.
107. Doronin, K.; Shashkova, E.V.; May, S.M.; Hofherr, S.E.; Barry, M.A. Chemical Modification with High Molecular Weight Polyethylene Glycol Reduces Transduction of Hepatocytes and Increases Efficacy of Intravenously Delivered Oncolytic Adenovirus. Hum. Gene Ther. 2009, 20, 975-988.
108. O'Riordan, C.R.; Song, A. PEGylated adenovirus for targeted gene therapy. Methods Mol. Biol. 2008, 434, 133-160.
109. Park, J.W.; Mok, H.; Park, T.G. Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus. Biochem. Biophys. Res. Commun. 2008, 366, 769-774.
110. Eto, Y.; Yoshioka, Y.; Mukai, Y.; Okada, N.; Nakagawa, S. Development of PEGylated adenovirus vector with targeting ligand. Int. J. Pharm. 2008, 354, 3-8.
111. Dhar, D.; Spencer, J.F.; Toth, K.; Wold, W.S.M. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J. Virol. 2009, 83, 2130-2139.
112. Thomas, M.A.; Spencer, J.F.; Wold, W.S.M. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors. Met. Mol. Med. 2007, 130, 169-183.
113. Jin, F.; Kretschmer, P.J.; Hermiston, T.W. Identification of novel insertion sites in the Ad5 genome that utilize the Ad splicing machinery for therapeutic gene expression. Mol. Ther. 2005, 12, 1052-1063.
114. Barton, K.N.; Paielli, D.; Zhang, Y.; Koul, S.; Brown, S.L.; Lu, M.; Seely, J.; Kim, J.H.; Freytag, S.O. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol. Ther. 2006, 13, 347-356.
115. Galanis, E.; Bateman, A.; Johnson, K.; Diaz, R.M.; James, C.D.; Vile, R.; Russell, S.J. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum. Gene Ther. 2001, 12, 811-821.
116. Ganesh, S.; Gonzalez, E.M.; Idamakanti, N.; Abramova, M.; Vanroey, M.; Robinson, M.; Yun, C.O.; Jooss, K. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. [erratum appears in Cancer Res. 2007 Jun 15;67(12):5998]. Cancer Res. 2007, 67, 4399-4407.
117. Kim, J.H.; Lee, Y.S.; Kim, H.; Huang, J.H.; Yoon, A.R.; Yun, C.O. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J. Natl. Cancer Inst. 2006, 98, 1482-1493.
118. Chen, M.J.; Green, N.K.; Reynolds, G.M.; Flavell, J.R.; Mautner, V.; Kerr, D.J.; Young, L.S.; Searle, P.F. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Gene Ther. 2004, 11, 1126-1136.
119. Freytag, S.O.; Rogulski, K.R.; Paielli, D.L.; Gilbert, J.D.; Kim, J.H. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Human Gene Ther. 1998, 9, 1323-1333.
120. Barton, K.N.; Stricker, H.; Brown, S.L.; Elshaikh, M.; Aref, I.; Lu, M.; Pegg, J.; Zhang, Y.; Karvelis, K.C.; Siddiqui, F.; Kim, J.H.; Freytag, S.O.; Movsas, B. Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol. Ther. 2008, 16, 1761-1769.
121. de Souza, A.P.; Bonorino, C. Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert. Rev. Anticancer Ther. 2009, 9, 1317-1332.
122. Endo, Y.; Sakai, R.; Ouchi, M.; Onimatsu, H.; Hioki, M.; Kagawa, S.; Uno, F.; Watanabe, Y.; Urata, Y.; Tanaka, N.; Fujiwara, T. Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation. Oncogene 2008, 27, 2375-2381.
123. Dougan, M.; Dranoff, G. Immune therapy for cancer. Ann. Rev. Immunol. 2009, 27, 83-117.
124. Lei, N.; Shen, F.B.; Chang, J.H.; Wang, L.; Li, H.; Yang, C.; Li, J.; Yu, D.C. An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors. Cancer Gene Ther. 2009, 16, 33-43.
125. Ramesh, N.; Ge, Y.; Ennist, D.L.; Zhu, M.; Mina, M.; Ganesh, S.; Reddy, P.S.; Yu, D.C. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer. Clin. Cancer Res. 2006, 12, 305-313.
126. Tagawa, M.; Kawamura, K.; Shimozato, O.; Ma, G.; Li, Q.; Suzuki, N.; Shimada, H.; Ochiai, T. Virology- and immunology-based gene therapy for cancer. Cancer Immunol. Immunother. 2006, 55, 1420-1425.
127. He, L.F.; Gu, J.F.; Tang, W.H.; Fan, J.K.; Wei, N.; Zou, W.G.; Zhang, Y.H.; Zhao, L.L.; Liu, X.Y. Significant antitumor activity of oncolytic adenovirus expressing human interferon-beta for hepatocellular carcinoma. J. Gene Med. 2008, 10, 983-992.
128. Su, C.; Peng, L.; Sham, J.; Wang, X.; Zhang, Q.; Chua, D.; Liu, C.; Cui, Z.; Xue, H.; Wu, H.; Yang, Q.; Zhang, B.; Liu, X.; Wu, M.; Qian, Q. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice. Mol. Ther. 2006, 13, 918-927.
129. Shashkova, E.V.; Spencer, J.F.; Wold, W.S.M.; Doronin, K. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol. Ther. 2007, 15, 598-607.
130. Lapteva, N.; Aldrich, M.; Weksberg, D.; Rollins, L.; Goltsova, T.; Chen, S.Y.; Huang, X.F. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J. Immunother. 2009, 32, 145-156.
131. Lee, Y.S.; Kim, J.H.; Choi, K.J.; Choi, I.K.; Kim, H.; Cho, S.; Cho, B.C.; Yun, C.O. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin. Cancer Res. 2006, 12, 5859-5868.
132. Haviv, Y.S.; Blackwell, J.L.; Li, H.; Wang, M.; Lei, X.; Curiel, D.T. Heat shock and heat shock protein 70i enhance the oncolytic effect of replicative adenovirus. Cancer Res. 2001, 61, 8361-8365.
133. Shashkova, E.V.; Kuppuswamy, M.N.; Wold, W.S.; Doronin, K. Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Ther. 2008, 15, 72.
134. Hawkins, L.K.; Hermiston, T.W. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region. Gene Ther. 2001, 8, 1142-1148.
135. Sova, P.; Ren, X.W.; Ni, S.; Bernt, K.M.; Mi, J.; Kiviat, N.; Lieber, A. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol. Ther. 2004, 9, 496-509.
136. Hanna, E.; Quick, J.; Libutti, S.K. The tumour microenvironment: a novel target for cancer therapy. Oral Dis. 2009, 15, 8-17.
137. Hood, J.D.; Bednarski, M.; Frausto, R.; Guccione, S.; Reisfeld, R.A.; Xiang, R.; Cheresh, D.A. Tumor regression by targeted gene delivery to the neovasculature.[see comment]. Science 2002, 296, 2404-2407.
138. Li, G.; Sham, J.; Yang, J.; Su, C.; Xue, H.; Chua, D.; Sun, L.; Zhang, Q.; Cui, Z.; Wu, M.; Qian, Q. Potent antitumor efficacy of an E1B 55kDa-deficient adenovirus carrying murine endostatin in hepatocellular carcinoma. Int. J. Cancer 2005, 113, 640-648.
139. Zhang, Z.; Zou, W.; Wang, J.; Gu, J.; Dang, Y.; Li, B.; Zhao, L.; Qian, C.; Qian, Q.; Liu, X. Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble FLT-1. Mol. Ther. 2004, 11, 553-562.
140. Yoo, J.Y.; Kim, J.H.; Kwon, Y.G.; Kim, E.C.; Kim, N.K.; Choi, H.J.; Yun, C.O. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth.[see comment]. Mol. Ther. 2007, 15, 295-302.
141. Sarkar, D.; Lebedeva, I.V.; Su, Z.Z.; Park, E.S.; Chatman, L.; Vozhilla, N.; Dent, P.; Curiel, D.T.; Fisher, P.B. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res. 2007, 67, 5434-5442.